GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » C4X Discovery Holdings PLC (LSE:C4XD) » Definitions » ROE %

C4X Discovery Holdings (LSE:C4XD) ROE % : 228.65% (As of Jan. 2024)


View and export this data going back to 2014. Start your Free Trial

What is C4X Discovery Holdings ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. C4X Discovery Holdings's annualized net income for the quarter that ended in Jan. 2024 was £35.60 Mil. C4X Discovery Holdings's average Total Stockholders Equity over the quarter that ended in Jan. 2024 was £15.57 Mil. Therefore, C4X Discovery Holdings's annualized ROE % for the quarter that ended in Jan. 2024 was 228.65%.

The historical rank and industry rank for C4X Discovery Holdings's ROE % or its related term are showing as below:

LSE:C4XD' s ROE % Range Over the Past 10 Years
Min: -143.7   Med: -92.36   Max: 70.93
Current: 70.93

During the past 12 years, C4X Discovery Holdings's highest ROE % was 70.93%. The lowest was -143.70%. And the median was -92.36%.

LSE:C4XD's ROE % is ranked better than
98.38% of 1360 companies
in the Biotechnology industry
Industry Median: -43.445 vs LSE:C4XD: 70.93

C4X Discovery Holdings ROE % Historical Data

The historical data trend for C4X Discovery Holdings's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

C4X Discovery Holdings ROE % Chart

C4X Discovery Holdings Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -143.70 -103.31 -28.11 -52.49 -121.19

C4X Discovery Holdings Semi-Annual Data
Jul14 Jan15 Jul15 Jan16 Jul16 Jan17 Jul17 Jan18 Jul18 Jan19 Jul19 Jan20 Jul20 Jan21 Jul21 Jan22 Jul22 Jan23 Jul23 Jan24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -52.41 -53.98 -61.19 -144.03 228.65

Competitive Comparison of C4X Discovery Holdings's ROE %

For the Biotechnology subindustry, C4X Discovery Holdings's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


C4X Discovery Holdings's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, C4X Discovery Holdings's ROE % distribution charts can be found below:

* The bar in red indicates where C4X Discovery Holdings's ROE % falls into.



C4X Discovery Holdings ROE % Calculation

C4X Discovery Holdings's annualized ROE % for the fiscal year that ended in Jul. 2023 is calculated as

ROE %=Net Income (A: Jul. 2023 )/( (Total Stockholders Equity (A: Jul. 2022 )+Total Stockholders Equity (A: Jul. 2023 ))/ count )
=-11.111/( (11.804+6.532)/ 2 )
=-11.111/9.168
=-121.19 %

C4X Discovery Holdings's annualized ROE % for the quarter that ended in Jan. 2024 is calculated as

ROE %=Net Income (Q: Jan. 2024 )/( (Total Stockholders Equity (Q: Jul. 2023 )+Total Stockholders Equity (Q: Jan. 2024 ))/ count )
=35.596/( (6.532+24.604)/ 2 )
=35.596/15.568
=228.65 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Jan. 2024) net income data. ROE % is displayed in the 30-year financial page.


C4X Discovery Holdings  (LSE:C4XD) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Jan. 2024 )
=Net Income/Total Stockholders Equity
=35.596/15.568
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(35.596 / 49.292)*(49.292 / 17.5035)*(17.5035 / 15.568)
=Net Margin %*Asset Turnover*Equity Multiplier
=72.21 %*2.8161*1.1243
=ROA %*Equity Multiplier
=203.35 %*1.1243
=228.65 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Jan. 2024 )
=Net Income/Total Stockholders Equity
=35.596/15.568
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (35.596 / 35.596) * (35.596 / 35.296) * (35.296 / 49.292) * (49.292 / 17.5035) * (17.5035 / 15.568)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 1.0085 * 71.61 % * 2.8161 * 1.1243
=228.65 %

Note: The net income data used here is two times the semi-annual (Jan. 2024) net income data. The Revenue data used here is two times the semi-annual (Jan. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


C4X Discovery Holdings ROE % Related Terms

Thank you for viewing the detailed overview of C4X Discovery Holdings's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


C4X Discovery Holdings (LSE:C4XD) Business Description

Traded in Other Exchanges
Address
53 Portland Street, Manchester One, Manchester, GBR, M1 3LD
C4X Discovery Holdings PLC is a drug discovery and development company. It has various proprietary and synergistic software platforms Taxonomy3, Conformetrix, and 4Sight. Taxonomy3 is a novel in silico platform technology that utilizes proprietary ground-breaking mathematical algorithms to perform complex multivariate analysis of genetic data. Conformetrix enables rational, accelerated 4D structural drug design using experimental data rather than theoretical data. The 4Sight allows its research scientists to view, understand and interrogate the complex, multidimensional molecular shape data of drug molecules.

C4X Discovery Holdings (LSE:C4XD) Headlines

No Headlines